Company overview
Ingenza is an engineering biology CRDMO specializing in industrial biotechnology and synthetic biology to deliver scalable bioprocesses for high-value industrial and therapeutic proteins. They offer microbial and mammalian manufacturing platforms, integrating chemical and biological processes for enhanced productivity. Services include proof-of-concept studies, fermentation development, cell line development, enzyme optimization, and AI/ML-driven protein expression tuning via their inGenius and codABLE platforms.
Ingenza is listed in the NovaPharmaNews Supplier Hub as a Life Science Reagents partner serving United States & Americas. Core focus areas include biotech crdmo, synthetic biology, fermentation development, therapeutic proteins, cell line development.
Industry categories: Life Science Reagents. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://www.ingenza.com
- Categories
- Life Science Reagents
- Markets served
- United States & Americas
- Keywords
- biotech crdmo, synthetic biology, fermentation development, therapeutic proteins, cell line development
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What bioprocess capabilities does Ingenza offer?
- Ingenza provides scalable bioprocesses using microbial and mammalian platforms, including fermentation scale-up, process demonstration, and integration of chemical/biological methods for industrial and therapeutic proteins.
- What are Ingenza's key technologies for R&D?
- Key platforms include inGenius for DoE-tailored fermentations, codABLE AI/ML for protein expression prediction, and cell line development with high-transfection human-derived lines for serum-free suspension cultures.
- Where are Ingenza's facilities located?
- Ingenza operates from purpose-built facilities in Edinburgh, Scotland, with over 12,000 sq ft at Roslin Innovation Centre, recently expanded for bioprocessing and research.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
